0.325  0.325 (100%)		11-25 16:00
Open: 0.325 High: 0.325 Volume: 7,229,138		Pre. Close: 0.325 Low: 0.325 Market Cap: 9(M)

Short term
Mid term
Targets	6-month :		1-year :
Resists	First :		Second :
Pivot price
Supports	First :		Second :
MAs	MA(5) :		MA(20) :
	MA(100) :		MA(250) :
MACD	MACD :		Signal :
%K %D	K(14,3) :		D(3) :
RSI	RSI(14):
52-week	High :		Low :

If tomorrow:	Open lower	Open higher
High:	-	-
Low:	-	-
Close:	-	-

Centogene N.V., along with its affiliates, operates globally with a primary focus on rare diseases. The company excels at converting diverse real-world data—spanning clinical, genetic, and other sources—into practical insights for patients, medical professionals, and pharmaceutical enterprises worldwide. Its activities are organized across three core divisions: Pharmaceutical, Diagnostics, and COVID-19 testing. At the heart of Centogene's strategy is its unique rare disease platform, a comprehensive repository of biological samples and integrated data. This platform consolidates epidemiological, phenotypic, and heterogenetic information, significantly improving the identification and ongoing surveillance of rare hereditary conditions. Furthermore, it plays a crucial role in accelerating the development of orphan drugs. The company provides an array of services within its Pharmaceutical segment, including target identification, early patient recruitment, epidemiological intelligence, biomarker discovery, and patient monitoring. Its Diagnostics arm offers genetic sequencing and diagnostic testing, reaching physicians, laboratories, and hospitals directly or through established distribution channels. Centogene also supplies COVID-19 testing solutions, covering both PCR and antigen tests. Established in 2006 and based in Rostock, Germany, Centogene N.V. holds key collaborative and licensing agreements with prominent partners such as Shire International GmbH, Pfizer Inc., Dr. Bauer Laboratoriums GmbH, Fraport AG, Takeda Pharmaceutical Company Limited, and Twist Bioscience Corporation.

Sat, 11 Jul 2026
If You Invested $1,000 in Centogene N.V. (CNTG) - Stock Titan

Wed, 12 Mar 2025
CENTOGENE Finalizes Private Equity Buyout: What Shareholders Need for Liquidation Payout - Stock Titan

Tue, 10 Jan 2023
Twist Bioscience and CENTOGENE Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics - Business Wire

Mon, 09 Jan 2023
Premier Research and CENTOGENE Launch Strategic Partnership to Accelerate and De-Risk Rare Disease Clinical Development - PR Newswire

Mon, 13 Jul 2026

Mon, 13 Jul 2026

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	(%)
Held by Institutions	(%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS
EPS Est Next Qtrly
EPS Est This Year
EPS Est Next Year
Book Value (p.s.)
Profit Margin	%
Operating Margin	%
Return on Assets (ttm)	%
Return on Equity (ttm)	%
Qtrly Rev. Growth	%
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth	%
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio
PEG Ratio
Price to Book value
Price to Sales
Price to Cash Flow

Dividend
Forward Dividend
Dividend Yield	0%
Dividend Pay Date
Ex-Dividend Date